Latest News and Press Releases

EWING, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or “the Company”) today announced that it has entered into an amendment to its existing loan and...

EWING, N.J., June 11, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James 2019...

EWING, N.J., May 30, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019...

EWING, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B....

EWING, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the first quarter ended March 31, 2019.  The...

EWING, N.J., April 18, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2019 financial results and recent operating progress before the...

EWING, N.J., March 28, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced receipt of orphan drug designation to evaluate the use of subcutaneous methotrexate (“MTX”) for...

EWING, N.J., March 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company...

EWING, N.J., March 04, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Karen Smith to the Company’s Board of Directors, filling the seat being...

Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue The Company Reaffirms 2019 Revenue Guidance of $95.0 to $105.0 Million EWING, N.J., Feb. 28, 2019 (GLOBE...